Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Transcatheter hepatic arterial chemoembolization using microencapsulated mitomycin C (MMCmc)].

S Takano1, M Fujii, T Tanaka

  • 13rd Dept. of Surgery, Nihon University, School of Medicine.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 1, 1988
PubMed
Summary

Hepatic arterial chemoembolization using microencapsulated mitomycin C (MMCmc) showed a 44% response rate in hepatocellular carcinoma patients. This treatment offers potential survival benefits, especially in Stage III, though liver function control is crucial.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The influence of interfering input from the peroneal nerve on tibial-nerve somatosensory evoked potential.

Electroencephalography and clinical neurophysiology·1992
Same author

Interaction of HTLV-1 Tax1 with p67SRF causes the aberrant induction of cellular immediate early genes through CArG boxes.

Genes & development·1992
Same author

[Clinical evaluation of intra-arterial methotrexate, vinblastine, doxorubicin and cis-platinum for bladder cancer].

Gan to kagaku ryoho. Cancer & chemotherapy·1992
Same author

[Clinical examination of acetated Ringer solution in patients with normal liver function and those with liver dysfunction].

Masui. The Japanese journal of anesthesiology·1992
Same author

Prevention of catheter-related sepsis during parenteral nutrition: effect of a new connection device.

JPEN. Journal of parenteral and enteral nutrition·1992
Same author

[Prognosis and treatment of non-Q-wave myocardial infarction].

Kokyu to junkan. Respiration & circulation·1992

Area of Science:

  • Oncology
  • Interventional Radiology
  • Pharmacology

Background:

  • Hepatocellular carcinoma (HCC) is a primary liver cancer with limited treatment options.
  • Hepatic arterial chemoembolization (HACE) is a locoregional therapy for HCC.
  • Microencapsulated mitomycin C (MMCmc) offers a novel approach to targeted chemotherapy delivery.

Observation:

  • Thirty-six HCC patients received HACE with MMCmc via the Soldinger method.
  • Dosages ranged from 10-40 mg per session, with total doses between 10-110 mg.
  • Infusion cannulae were placed in the hepatic artery for targeted delivery.

Findings:

  • A 44% objective response rate was observed, with 12 partial responses in 27 evaluable lesions.
  • Serum alpha-fetoprotein (AFP) levels decreased in 70% of patients.

Related Experiment Videos

  • The 12-month survival rate was 35% overall and 67% for Stage III HCC.

    • Implications:

    • HACE with MMCmc demonstrates anti-tumor efficacy and potential survival improvement in HCC.
    • Maintaining liver function is critical, as hepatic failure and esophageal varices are significant causes of mortality.
    • Reported side effects (fever, pain) were generally mild, suggesting a manageable safety profile.